Sera Prognostics, Inc.

NasdaqGM SERA

Sera Prognostics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -782.98%

Sera Prognostics, Inc. Gross Profit Margin is -782.98% for the Trailing 12 Months (TTM) ending September 30, 2024, a -3,139.80% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Sera Prognostics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 25.76%, a -27.18% change year over year.
Sera Prognostics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 35.37%, a -39.08% change year over year.
Sera Prognostics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 58.06%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: SERA

Sera Prognostics, Inc.

CEO	Ms. Evguenia Lindgardt M.B.A.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way
Employees	55
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Research & Consulting

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years